Compensation 990
OrganizationsEmployeesBoard MembersGrantsContractorsTop RankingsPricing

Stay updated on 990 organization compensation

© Civic Register LLC

Compensation 990 is an independent service that uses public IRS Form 990 filings as its source data. We clean and standardize this information, but the original filings may contain errors or omissions. Years on this site refer to the organization’s fiscal year end date on the filing.

About•Report a discrepancy•Your privacy choices
Organizations Medical Research Foundation for Angelman Syndrome Therapeutics

Foundation for Angelman Syndrome Therapeutics

Fiscal year ending 2024. Filed on September 30, 2025.

5900 Balcones Drive 8754
Austin, Texas 78731

Foundation for Angelman Syndrome Therapeutics (EIN: 26-3160079) has filed an IRS Form 990 since at least fiscal year 2016. In its fiscal year 2024 IRS Form 990 filing, Foundation for Angelman Syndrome Therapeutics, a 501(c)(3) charitable organization, reported compensation for 5 out of 11 total employees. Among the employees shown here, the average compensation is $296,742. The highest compensated employee at Foundation for Angelman Syndrome Therapeutics is Allyson Berent with fiscal year 2024 compensation of $509,945.

Revenue, expenses, and employee compensation

Revenue

$5,388,260

Expenses

$10,391,969

Employee compensation

$2,926,752
Revenue, expenses, and employee compensation over time

Reported Compensated Employees

Allyson Berent
Chief Science Officer
$509,945
$0 $509,945 No other comp
Ryan K Fischer
Chief Operating Oficer
$286,130
$286,130 No related compNo other comp
Alana Newhouse
President and Chief Executive Officer
$245,000
$245,000 No related compNo other comp
Kena Pearson
Chief Financial Officer
$232,568
$232,568 No related compNo other comp
Michele Golombuski
Chief Development Officer
$210,068
$210,068 No related compNo other comp

Benchmark Employee Compensation

Non-Employee Board Members

Amelia Beatty
Secretary
Ben O'Connor
Director
Guy Shapiral
Treasurer
John Schlueter
Director
Karly Warner
Director
Kelly David
Director
Lauren Hoffer
Director
Michael Hanrahan
VICE Chairperson and TR
Nora Xu
Director
Roy Azout
Director
Ryan Jacob
Chair

Contractors

Faegre Drinker Biddle & Reath LLP
Advocacy Firm
$324,783
Van Ness Creative Strategies LLC
Marketing
$297,590
Choate Hall Stewart LLP
Legal
$204,561
Maiddy Dunigan
Conulting
$183,985
Jessica Dobson Weaver
Board Consultant
$131,250

Mission Statement

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Revisions to this organization profile

September 30, 2025:
2024 Foundation for Angelman Syndrome Therapeutics 990 filed
November 16, 2024:
2023 Foundation for Angelman Syndrome Therapeutics 990 filed
November 16, 2023:
2022 Foundation for Angelman Syndrome Therapeutics 990 filed

Get an email when new compensation information is released for Foundation for Angelman Syndrome Therapeutics

Be the first to know when new IRS Form 990 data is published for this organization.

Related Jobs

View more jobs
Powered by Talroo
Report a discrepancy →